论文部分内容阅读
目的:探究坎地沙坦酯联合银杏注射液对慢性肺心病急性加重期患者肺动脉压、血管内皮生长因子水平及临床疗效的影响。方法:收集我院诊治的慢性肺心病急性加重期患者134例,随机分为对照组和试验组,每组67例。对照组患者口服坎地沙坦酯片治疗,试验组患者在对照组基础上联合静脉滴注银杏注射液治疗。观察并比较两组患者的临床疗效、治疗前后的肺动脉压及血管内皮生长因子水平变化情况。结果:治疗后,两组肺动脉压及血管内皮生长因子水平均较治疗前显著降低(P<0.05),与对照组相比,试验组患者治疗总有效率较高(P<0.05),肺动脉压及血管内皮生长因子水平较低(P<0.05)。结论:坎地沙坦酯联合银杏注射液对慢性肺心病急性加重期患者疗效明显,能够有效降低肺动脉压,可能与降低血管内皮生长因子水平有关。
Objective: To investigate the effect of candesartan cilexetil and gingko injection on pulmonary arterial pressure, vascular endothelial growth factor and clinical effect in patients with acute exacerbation of chronic pulmonary heart disease. Methods: A total of 134 patients with acute exacerbation of chronic pulmonary heart disease who were diagnosed and treated in our hospital were randomly divided into control group and experimental group, with 67 cases in each group. The patients in the control group were treated with candesartan cilexetil, and the patients in the test group were treated with intravenous infusion of Ginkgo biloba on the basis of the control group. To observe and compare the clinical efficacy of two groups of patients before and after treatment of pulmonary arterial pressure and vascular endothelial growth factor levels. Results: After treatment, the levels of pulmonary arterial pressure and vascular endothelial growth factor in both groups were significantly lower than those before treatment (P <0.05). Compared with the control group, the treatment group had a higher total effective rate (P <0.05) and pulmonary arterial pressure And lower levels of vascular endothelial growth factor (P <0.05). CONCLUSION: Candesartan cilexetil and gingko biloba injection have obvious curative effect on patients with acute exacerbation of chronic pulmonary heart disease, and can effectively reduce pulmonary arterial pressure, which may be related to the decrease of the level of vascular endothelial growth factor.